Search

Performance status may alter outcomes in those treated with abiraterone

The drug therapies available for those with metastatic castrate-resistant prostate cancer have increased over the past few years. Abiraterone, a CYP17 inhibitor, has been proven effective in phase three trials, however those with poor performance status were largely under-represented in...

Cord compression in cancer

This article will be of great interest to uro-oncologists. Vertebral metastasis occurs in 3-5% of all cancers (most commonly in prostate, breast and lung cancer). It can cause pain, vertebral collapse and cord compression. Data from the National Institute for...

Intermittent vs. continuous hormonal therapy for metastatic prostate cancer

Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...

Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel

This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy

There is increasing evidence for the role of radical prostatectomy in select patients with T3-T4 prostate cancer (as part of multimodal therapy). This retrospective multicentre study explored the benefit of neoadjuvant hormonal therapy before radical prostatectomy specifically in patients with...

Active surveillance for intermediate-risk prostate cancer

In this review, Klotz and Dall’Era summarise available data from the Toronto, UCSF, ERSPC, PASS and Royal Marsden active surveillance cohorts, looking specifically at outcomes of patients classed as intermediate risk. Cancer specific survival in men managed initially with active...